Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 4, 2009, Pages 895-899

  Soyer, Ozge Uysal ^a   Aytac, Selin ^a   Tuncer, Ayfer ^a   Cetin, Mualla ^a   Yetgin, Sevgi ^a   Sekerel, Bulent Enis ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; allergy; child; desensitization; L asparaginase; premedication

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; HYDROXYZINE; METHYLPREDNISOLONE; RANITIDINE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; COUGHING; CYANOSIS; DESENSITIZATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ESCHERICHIA COLI; FEMALE; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STRIDOR; TREATMENT DURATION; URTICARIA; VOMITING; WHEEZING;

ADOLESCENT; ALGORITHMS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES;

EID: 63449092729     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.10.034     Document Type: Article

References (29)

1. Graham M.L. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 55 (2003) 1293-1302
2. Fu C.H., and Sakamoto K.M. PEG-asparaginase. Expert Opin Pharmacother 8 (2007) 1977-1984
3. Woo M.H., Hak L.J., Storm M.C., Evans W.E., Sandlund J.T., Rivera G.K., et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12 (1998) 1527-1533
4. Narta U.K., Kanwar S.S., and Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 61 (2007) 208-221
5. Pratt C.B., Simone J.V., Zee P., Aur R.J., and Johnson W.W. Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia. J Pediatr 77 (1970) 474-483
6. Cheung N.K., Chau I.Y., and Coccia P.F. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 8 (1986) 99-104
7. Pratt C.B., Choi S.I., and Holton C.P. Low-dosage asparaginase treatment of childhood acute lymphocytic leukemia. Am J Dis Child 121 (1971) 406-409
8. Haskell C.M., and Canellos G.P. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol 18 (1969) 2578-2580
9. Hak L.J., Relling M.V., Cheng C., Pei D., Wang B., Sandlund J.T., et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18 (2004) 1072-1077
10. Wang B., Relling M.V., Storm M.C., Woo M.H., Ribeiro R., Pui C.-H., et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17 (2003) 1583-1588
11. Tallal L., Tan C., Oettgen H., Wollner N., McCarthy M., Helson L., et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 25 (1970) 306-320
12. Clarkson B., Krakoff I., Burchenal J., Karnofsky D., Golbey R., Dowling M., et al. Clinical results of treatment with E coli L asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer 25 (1970) 279-305
13. Bonno M., Kawasaki H., Hori H., Umemoto M., Komada Y., and Sakurai M. Rapid desensitization for L-asparaginase hypersensitivity. J Allergy Clin Immunol 101 (1998) 571-572
14. Unal S., Yetgin S., Cetin M., Gümrük F., Arslan D., Ozyürek E., et al. The prognosis and survival of childhood acute lymphoblastic leukemia with central nervous system relapse. Pediatr Hematol Oncol 21 (2004) 279-289
15. Brown A.F., McKinnon D., and Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 108 (2001) 861-866
16. Sampson H.A., Muñoz-Furlong A., Campbell R.L., Adkinson Jr. N.F., Bock S.A., Branum A., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117 (2006) 391-397
17. Jaffe N., Traggis D., Das L., Moloney W.C., Hann H.W., Kim B.S., et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 31 (1971) 942-949
18. Woo M.H., Hak L.J., Storm M.C., Sandlund J.T., Ribeiro R.C., Rivera G.K., et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 18 (2000) 1525-1532
19. Nesbit M., Chard R., Evans A., Karon M., and Hammond G.D. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1 (1979) 9-13
20. Billett A.L., Carls A., Gelber R.D., and Sallan S.E. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 70 (1992) 201-206
21. Larson R.A., Fretzin M.H., Dodge R.K., and Schiffer C.A. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 12 (1998) 660-665
22. US Food and Drug Administration. FDA approves oncaspar for newly diagnosed acute lymphoblastic leukemia. 2006. Available at: www.fda.gov/bbs/topics/NEWS/2006/NEW01419.html. Accessed November 25, 2008.
23. Asselin B.L., Whitin J.C., Coppola D.J., Rupp I.P., Sallan S.E., and Cohen H.J. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11 (1993) 1780-1786
24. Müller H.J., and Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28 (1998) 97-113
25. Körholz D., Wahn U., Jürgens H., and Wahn V. Allergic reactions in treatment with L-asparaginase. Significance of specific IgE antibodies. Monatsschr Kinderheilkd 138 (1990) 23-25
26. Fabry U., Körholz D., Jürgens H., Göbel U., and Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism. Pediatr Res 19 (1985) 400-408
27. Killander D., Dohlwitz A., Engstedt L., Franzén S., Gahrton G., Gullbring B., et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 37 (1976) 220-228
28. Zalewska-Szewczyk B., Andrzejewski W., and Bodalski J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 43 (2004) 600-602
29. Zalewska-Szewczyk B., Andrzejewski W., Mlynarski W., Jedrychowska-Dańska K., Witas H., and Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 48 (2007) 931-936